立方製藥(003020.SZ):洛索洛芬鈉口服溶液藥品註冊上市許可申請獲得受理
格隆匯5月20日丨立方製藥(003020.SZ)公佈,近日,合肥立方製藥股份有限公司全資子公司合肥誠志生物製藥有限公司收到國家藥品監督管理局下發的洛索洛芬鈉口服溶液藥品註冊上市許可申請的《受理通知書》。
洛索洛芬鈉是一種苯丙酸類非甾體抗炎藥,具有較好的鎮痛、消炎、解熱作用,尤其是鎮痛作用較強。其適應症為:①類風濕關節炎、骨性關節炎、腰痛症、肩關節周圍炎、頸肩腕綜合徵、牙痛的消炎和鎮痛;②手術後,外傷後及拔牙後的鎮痛和消炎;③急性上呼吸道炎(包括伴有急性支氣管炎的急性上呼吸道炎)的解熱和鎮痛。本品原研為日本日醫工株式會社。截至公吿日,國內尚無洛索洛芬鈉口服溶液進口批文,有1家企業持有該產品國產藥品批文。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.